UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 22, 2004
RIGEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
0-29889 | | 94-3248524 |
(Commission File No.) | | (IRS Employer Identification No.) |
1180 Veterans Boulevard
South San Francisco, CA 94080
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (650) 624-1100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On November 22, 2004, Rigel Pharmaceuticals, Inc. announced the results from its Phase I/II clinical study of R803, a novel oral hepatitis C RNA polymerase inhibitor. The press release dated November 22, 2004, titled “Poor Bioavailability Results In Insignificant Clinical Effects For Rigel R803 In Phase I/II HCV Trial,” is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Neither the filing of the press release as an exhibit to this Current Report on Form 8-K nor the inclusion in that press release of a reference to Rigel’s internet address shall, under any circumstances, be deemed to incorporate the information available at that internet address into this Current Report on Form 8-K. The information available at Rigel’s internet address is not part of this Current Report on Form 8-K or any other report filed by Rigel with the Securities and Exchange Commission.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. | | Description | |
99.1 | | Press Release, dated November 22, 2004, entitled “Poor Bioavailability Results In Insignificant Clinical Effects For Rigel R803 In Phase I/II HCV Trial.” | |
2
